OA11836A - Controlled release formulation for treating COPD. - Google Patents

Controlled release formulation for treating COPD. Download PDF

Info

Publication number
OA11836A
OA11836A OA1200100217A OA1200100217A OA11836A OA 11836 A OA11836 A OA 11836A OA 1200100217 A OA1200100217 A OA 1200100217A OA 1200100217 A OA1200100217 A OA 1200100217A OA 11836 A OA11836 A OA 11836A
Authority
OA
OAPI
Prior art keywords
formulation
inhibitor
daims
pde4
amount
Prior art date
Application number
OA1200100217A
Other languages
English (en)
Inventor
Patrick G Faulkner
Jaime J Lucca
Thomas J Wrzosek
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of OA11836A publication Critical patent/OA11836A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200100217A 1999-02-23 2000-02-22 Controlled release formulation for treating COPD. OA11836A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12129199P 1999-02-23 1999-02-23

Publications (1)

Publication Number Publication Date
OA11836A true OA11836A (en) 2005-08-22

Family

ID=22395738

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100217A OA11836A (en) 1999-02-23 2000-02-22 Controlled release formulation for treating COPD.

Country Status (29)

Country Link
US (1) US20030211152A1 (no)
EP (1) EP1154758A4 (no)
JP (1) JP2002537320A (no)
KR (1) KR20010112279A (no)
CN (1) CN1195496C (no)
AR (1) AR028986A1 (no)
AU (1) AU3501500A (no)
BG (1) BG105905A (no)
BR (1) BR0008382A (no)
CA (1) CA2366747A1 (no)
CO (1) CO5150233A1 (no)
CZ (1) CZ20013025A3 (no)
EA (1) EA200100906A1 (no)
HK (1) HK1043045A1 (no)
HU (1) HUP0200134A3 (no)
ID (1) ID29792A (no)
IL (1) IL144603A0 (no)
MA (1) MA25386A1 (no)
MY (1) MY121142A (no)
NO (1) NO20014049L (no)
NZ (1) NZ527716A (no)
OA (1) OA11836A (no)
PE (1) PE20001496A1 (no)
PL (1) PL350287A1 (no)
SK (1) SK12072001A3 (no)
TR (1) TR200102448T2 (no)
TW (1) TWI224013B (no)
WO (1) WO2000050011A1 (no)
ZA (1) ZA200106803B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032165A1 (en) * 1999-10-29 2001-05-10 Smithkline Beecham Corporation Method for administering a phosphodiesterase 4 inhibitor
WO2002094321A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
HUP0500078A3 (en) * 2001-09-19 2010-07-28 Nycomed Gmbh Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
BR0318535A (pt) * 2003-09-30 2006-09-12 Lupin Ltd composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
CN101849921A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
EP4282414A3 (en) * 2019-01-15 2024-02-21 UNION therapeutics A/S Modified release tablet formulations containing phosphodiesterase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636568A (no) * 1961-01-31
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
BG105905A (bg) 2002-04-30
NO20014049D0 (no) 2001-08-20
SK12072001A3 (sk) 2002-01-07
TR200102448T2 (tr) 2003-03-21
AR028986A1 (es) 2003-06-04
CA2366747A1 (en) 2000-08-31
MA25386A1 (fr) 2002-04-01
TWI224013B (en) 2004-11-21
IL144603A0 (en) 2002-05-23
EP1154758A1 (en) 2001-11-21
HUP0200134A2 (hu) 2002-05-29
AU3501500A (en) 2000-09-14
EP1154758A4 (en) 2007-09-05
WO2000050011A1 (en) 2000-08-31
CO5150233A1 (es) 2002-04-29
NO20014049L (no) 2001-10-22
PE20001496A1 (es) 2001-02-08
BR0008382A (pt) 2002-02-05
HK1043045A1 (zh) 2002-09-06
MY121142A (en) 2005-12-30
ID29792A (id) 2001-10-11
NZ527716A (en) 2005-03-24
CN1347314A (zh) 2002-05-01
EA200100906A1 (ru) 2002-02-28
CN1195496C (zh) 2005-04-06
JP2002537320A (ja) 2002-11-05
US20030211152A1 (en) 2003-11-13
KR20010112279A (ko) 2001-12-20
HUP0200134A3 (en) 2003-03-28
ZA200106803B (en) 2002-08-19
PL350287A1 (en) 2002-12-02
CZ20013025A3 (cs) 2002-07-17

Similar Documents

Publication Publication Date Title
US4753801A (en) Sustained release tablets
JP4885896B2 (ja) レボドパ／カルビドパ／エンタカポン医薬製剤
EP0264187B1 (en) Pharmaceutical composition containing ibuprofen and aluminium hydroxide
US20030175338A1 (en) Formulations of atorvastatin stabilized with alkali metal additions
OA11836A (en) Controlled release formulation for treating COPD.
JP2007314578A (ja) 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠
US20160158203A1 (en) Methods of treatment with bioavailable compositions of metaxalone comprising nonvolatile liquids
SK138099A3 (en) Extended release formulations of erythromycin derivatives
US20030044462A1 (en) Sustained release tablets containing bupropion hydrochloride
JPS6241646B2 (no)
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
KR20020050249A (ko) 포스포디에스테라제 4 억제제의 투여 방법
SK281193B6 (sk) Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy
US6713509B1 (en) Controlled release formulation for treating COPD
US20050169991A1 (en) Sustained release torsemide dosage forms
AU2003202879A1 (en) Drug delivery system for sustained delivery of glipizide
AU2004201503A1 (en) Controlled Release Formulation for Treating COPD
JP2006520770A (ja) フィブレートを含有する錠剤の形の製薬組成物の製造方法、および該方法に従って得られた錠剤
MXPA01008523A (en) Controlled release formulation for treating copd
JP2022517616A (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
RU2354358C1 (ru) Твердая лекарственная форма матричного типа, обладающая противовоспалительной, анальгезирующей, жаропонижающей активностью, с пролонгированным высвобождением, и способ ее получения
JP3850473B2 (ja) 持続性錠剤
WO2011093535A1 (ko) 갈란타민을 포함한 매트릭스 형태의 약학 조성물
HU186607B (en) Process for preparing pharmaceutical composition with synergetic antiinflammatory activity